XBIO REPORT

  • WEEKLY BIOTECH STOCK CATALYST REPORTS
  • OPTION SCREENERS
  • February 7, 2026

    Pharos AI and 10x Genomics Join Forces to Advance Cancer Research Through Integrated Technology

    NASDAQ: $TXG A significant collaboration has been established between Pharos AI, a leader in artificial intelligence solutions for the life sciences, and 10x Genomics, a pioneer in single cell and spatial biology technologies. This partnership is set to revolutionize how researchers approach complex challenges in oncology by integrating advanced computational power with cutting-edge molecular analysis.…

    Artificial Intelligence
    $TXG, artificial-intelligence, Cancer Research, Genomics, Spatial Biology, Translational Medicine
  • February 7, 2026

    Metavia’s Collaboration with Syntekabio Yields Positive AI Modeling Results for Vanoglipel

    NASDAQ: $MTVA Metavia, Inc., a company focused on novel therapeutic development, recently announced encouraging results stemming from its ongoing artificial intelligence (AI) modeling collaboration with Syntekabio. These latest findings solidify key therapeutic targets relevant to their lead compound, Vanoglipel, a promising drug candidate. The collaboration leverages Syntekabio’s advanced AI platforms to expedite and refine the…

    Artificial Intelligence
    $MTVA, AI Drug Discovery, Metavia, Syntekabio, Therapeutic Targets, Vanoglipel
  • February 7, 2026

    Viatris Announces Q4 and Full-Year 2025 Financial Results Date and Investor Event Schedule

    NASDAQ: $VTRS Viatris Inc. has officially announced the schedule for reporting its financial outcomes for the fourth quarter and the entirety of the 2025 fiscal year. This important update for investors and stakeholders is set for release on Thursday, February 26, 2026. Following the release of the comprehensive financial figures, Viatris will host a conference…

    Stocks
    $VTRS, Corporate Announcement, Financial Results, Investor Event, Q4 2025, Viatris
  • February 7, 2026

    Amgen’s 2025 Financial Performance: A Review of Fourth Quarter and Full-Year Results

    NASDAQ: $AMGN Amgen recently announced its financial results for the fourth quarter and the full year ended December 31, 2025. The company’s performance reflects ongoing strategic initiatives and the impact of its evolving portfolio in the biotechnology sector. For the fourth quarter of 2025, Amgen reported total revenue of approximately $8.2 billion. This figure marks…

    Stocks
    $AMGN, Amgen, Biotechnology, Financial Results, Pharma Earnings, Q4 2025
  • February 7, 2026

    Rigel Strengthens Leadership with Appointment of Michael P. Miller to Board of Directors

    NASDAQ: $RIGL Rigel Pharmaceuticals, Inc. recently announced a significant addition to its leadership structure with the appointment of Michael P. Miller to its Board of Directors, effective immediately. Mr. Miller brings a wealth of experience in the biotechnology and pharmaceutical sectors, promising to contribute valuable strategic insights as Rigel continues to advance its pipeline and…

    Announcements
    $RIGL, Biotechnology, Board Appointment, Corporate Governance, Michael P. Miller, Rigel Pharmaceuticals
  • February 7, 2026

    Avidity Biosciences Sets Record Date for Potential Spin-Off of RNA Therapeutics Business

    NASDAQ: $RNA Avidity Biosciences, Inc. has recently announced a significant corporate development concerning its RNA therapeutics business. The company has established an expected record date for the potential separation of its RNA therapeutics business into an independent, publicly traded entity. The Potential Spin-Off Explained In a move designed to potentially maximize shareholder value and allow…

    Announcements
    $RNA, Avidity Biosciences, Biotechnology, Corporate Action, RNA Therapeutics, Spin-Off
  • February 7, 2026

    ADC Therapeutics Strengthens Team with New Employee Inducement Grants

    NYSE: $ADCT ADC Therapeutics SA, a commercial-stage, late-stage biotechnology company focused on the development and commercialization of antibody drug conjugates (ADCs) for patients suffering from cancer, recently announced a significant commitment to its growing workforce. In a filing dated December 17, 2024, the company disclosed the granting of equity awards to newly hired employees under…

    Announcements
    $ADCT, ADC Therapeutics, Biotechnology, Employee Incentives, Equity Grants, oncology
  • February 7, 2026

    Anixa Biosciences Advances CAR-T Therapy with U.S. Adopted Name Approval

    NASDAQ: $ANIX Anixa Biosciences, Inc., a biotechnology company focused on the development of innovative cancer therapies, has reached a significant milestone in the progression of its CAR-T cell therapy candidate. The company announced that the United States Adopted Names (USAN) Council has approved the non-proprietary name for its novel CAR-T therapy. This approval of a…

    Announcements
    $ANIX, Anixa Biosciences, Biotechnology, CAR-T Therapy, oncology, USAN Council
  • February 7, 2026

    Edgewise Therapeutics Announces Inducement Grants Under Nasdaq Rules

    NASDAQ: $EWTX Edgewise Therapeutics Reports Inducement Grants as Permitted by Nasdaq Listing Rules Edgewise Therapeutics, Inc., a company focused on developing transformative therapies for muscular dystrophies, has recently announced the issuance of new equity awards. These grants were made as inducement awards to newly hired non-executive employees, a practice fully compliant with the Nasdaq Stock…

    Announcements
    $EWTX, Biopharma, Edgewise Therapeutics, Equity Awards, Inducement Grants, Nasdaq Compliance
  • February 7, 2026

    SBC Medical Supported Nasukai and Daibi Medical Aesthetics Forge Strategic Alliance to Enhance Patient Care

    NASDAQ: $SBC SBC Medical Supported Medical Corporation Nasukai, a prominent entity in the medical sector, today announced the formation of a significant strategic alliance with Daibi Medical Aesthetics. This collaboration marks a pivotal moment for both organizations, signaling a commitment to expanding high-quality medical services and enhancing patient experience across their respective domains. SBC is…

    Growth
    $SBC, Aesthetic Medicine, Healthcare Partnership, Medical Corporation, SBC Medical Nasukai, Strategic Alliance
Previous Page
1 2 3 4 5 … 11
Next Page

© XBioReport.com